NovAccess Global

05/21/2024

https://novaccessglobal.com/wp-content/uploads/2024/05/5_21_24-NovAccess-Global-Cedars-IDH1-Patent-Press-Release.pdf

04/30/2024

https://novaccessglobal.com/wp-content/uploads/2024/04/4_30_24-NovAccess-Global-Announces-New-License-to-Advance-its-Immunotherapy-Platform.pdf

03/04/2024

https://novaccessglobal.com/wp-content/uploads/2024/03/3_1_24-NovAccess-Global-Provides-Business-Updates-and-Announces-Scheduling-of-Annual-Meeting-of-Shareholders.pdf

01/02/2024

NovAccess Global Announces $10.7 Million Financing

12/04/2023

NovAccess Global Inc. to Present at the December 7th Virtual Investor Summit
https://novaccessglobal.com/wp-content/uploads/2023/12/NovAccess-Global-Inc.-December-7th-PR-.pdf

10/04/2023

https://shared.outlook.inky.com/link?domain=www.uc.edu&t=h.eJxFjktygzAQRK_iYh0hkBAfr3yVsRhAFX2o0chUnMrdY7zxtl91v_6tCvnqeqk25j1fpTyOoy62xrnIiEeWQOysxyxVo7RsOlmswEjJexdXsQM7jJyFi2JHyimCd0-chQuhxMQbEuw_YvUu3T1kTgEEkwNfbxx89XWpvk95RE60LtwbMwytlvNC8ES6xfQAazHn1af7q2RTkIPSZtI4TNbCMmBvuqZtlLKTatCME8i2H7UxndFj3ZlTgaciA8HGhI_Xp3RbA7j33Mnnk3-Sv398TFs6.MEUCIQCz2CqFvSI7eOu0sOGHQ2mCqz5GrhWHQP49osZqifWuPAIgHtGhKqVyFJ_G_8QnMBFs5n4OPaIG4GGvqQgF-jtcRP8

The University of Cincinnati is enrolling patients in an Imvax study that will test the effectiveness of a personalized vaccine approach to fight deadly brain tumors.

09/06/2023

https://www.drugtargetreview.com/news/108724/improving-immunotherapy-against-brain-cancer/

US scientists suggest that anti-angiogenesis drugs could improve the function and delivery of CAR-T cell therapy.

08/21/2023

https://www.cityofhope.org/targeting-glioblastoma-cancer-killing-virus

Glioblastoma is a virtually incurable brain cancer with a five-year-survival rate of only 10%. “It’s heartbreaking to keep telling people in clinic that we don’t have a cure,” said Jana Portnow, M.D., co-director of City of Hope’s Brain Tumor Program. “This is a tough tumor, and these pa...

08/09/2023

https://www.targetedonc.com/view/discussing-immunotherapies-and-targeted-therapies-in-brain-cancer

Patrick Wen, MD, looks at how emerging evidence has shown promise for targeting mutations in patients with glioblastomas when it was once believed these therapies may not work for these patients.